Form 4: Castle Biosciences COO Reports Equity Transactions

Castle Biosciences' Chief Operating Officer, Kristen M. Oelschlager, reported recent transactions involving common stock and restricted stock units, including tax withholdings and RSU conversions.

Summary

• Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences Inc., reported several transactions involving the company's common stock and Restricted Stock Units (RSUs).
• On March 3, 2026, 2,427 shares of common stock were withheld to satisfy tax obligations related to vested performance stock units, at a price of $27.57 per share.
• On March 4, 2026, 25,771 shares of common stock were acquired through the conversion of derivative securities (RSUs).
• Also on March 4, 2026, 6,792 shares of common stock were withheld for tax purposes at a price of $28.17 per share.
• The COO acquired 48,367 new Restricted Stock Units (RSUs) on March 3, 2026, which are scheduled to vest in four equal annual installments beginning on March 3, 2027.
• An additional 13,811 RSUs, part of a grant from March 4, 2024 (totaling 55,243 RSUs), converted to common stock on March 4, 2026. These RSUs vest in four equal installments starting March 4, 2025.
• Another 11,960 RSUs, part of a grant from March 4, 2025 (totaling 47,838 RSUs), converted to common stock on March 4, 2026. These RSUs vest in four equal installments starting March 4, 2026.
• Following these transactions, Kristen M. Oelschlager directly owns 39,047 shares of common stock and 35,878 Restricted Stock Units.
• An additional 97,251 shares of common stock are indirectly owned through The Fritz Shorter Trust, where the reporting person and her spouse serve as trustees and beneficiaries.
• The reported common stock holdings also include 965 shares acquired on February 27, 2026, under the Issuer's employee stock purchase plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting routine executive compensation activities including new RSU grants and employee stock purchases, which align management's interests with the company's long-term success.

Positives

• Kristen M. Oelschlager received a new grant of 48,367 Restricted Stock Units (RSUs) on March 3, 2026, representing future equity compensation.
• The conversion of 25,771 RSUs into common stock on March 4, 2026, indicates successful vesting of previously granted equity awards.
• The acquisition of 965 shares on February 27, 2026, through the employee stock purchase plan demonstrates continued insider investment in the company.

Future Outlook

The reporting person has future equity compensation tied to the company's performance, with 48,367 Restricted Stock Units scheduled to vest in four equal annual installments beginning on March 3, 2027, indicating continued alignment of management incentives with shareholder interests.

Industry Context

StockSavvy.ai notes that these transactions are typical for executive compensation packages in the biotechnology and healthcare sectors, where equity awards like Restricted Stock Units are a common mechanism to align management incentives with long-term company performance and shareholder value. The combination of RSU grants, vesting, and associated tax withholdings reflects standard compensation practices.

Related Party Transactions

• Kristen M. Oelschlager indirectly owns 97,251 shares of common stock through The Fritz Shorter Trust, where she and her spouse are trustees and beneficiaries.

Stakeholder Impact

• Shareholders: These transactions provide transparency into executive compensation and equity holdings, which can influence investor confidence.
• Employees: The reporting person's participation in the employee stock purchase plan highlights a benefit available to employees.

Next Steps

• The 48,367 Restricted Stock Units acquired on March 3, 2026, will begin vesting in four equal annual installments starting March 3, 2027.

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation, including RSU grants, vesting, and tax withholdings, along with an employee stock purchase. These are standard events and do not indicate a material change in the company's fundamentals or provide a strong signal for a buy or sell recommendation. Therefore, a 'hold' recommendation is appropriate for seasoned investors.

Keywords

Castle Biosciences, CSTL, Insider Transaction, Form 4, Restricted Stock Units, RSU, Common Stock, Equity Compensation, Stock Purchase Plan, Tax Withholding